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INTRODUCTION
Multiple endocrine neoplasia type 1 (MEN 1) is a familial
tumor syndrome characterizing tumors of the parathyroid
glands, the enteropancreatic neuroendocrine system, the ante-
rior pituitary gland, and the skin. The most common endo-
crine tumors are parathyroid tumors, which cause hyperpar-
athyroidism and hypercalcemia. Other tumors of MEN 1 in-
clude gastrinomas, insulinomas, prolactinomas, and carcinoid
tumors.
Gastrinoma is the most frequent functional pancreaticodu-
odenal endocrine tumor in patients with MEN 1 and a major
determinant of mortality when stricken with this syndrome
(1). The gastrinoma form of MEN 1 often arises from the gas-
trinoma triangle, a region including the cystic and common
bile ducts, second and third portions of the duodenum, and
the head and body of the pancreas (2). However, gastrinomas
can also appear in other locations, such as the stomach, the
ovaries, or the liver, although the tendency to arise from these
locations is infrequent (3). Here we report the case of woman
with MEN1 arising as primary hepatic gastrinoma.
CASE REPORT
A 39-yr-old woman with a 1-yr history of several hospital
admissions resulting from abdominal pain, nausea, and vom-
iting and who had a primary closure and omental patch oper-
ation for an acute surgical abdomen resulting from a sponta-
neous perforation of the duodenum a year ago was admitted
to hospital because of a change in mental status. The proton
pump inhibitor pantoprazole proved curative for many of her
gastrointestinal symptoms during this 1-yr time period. Addi-
tional medical history included a craniotomy in 1980, hav-
ing resulted from the diagnosis of pituitary macroadenoma.
Laboratory results upon admission demonstrated a low blo-
od glucose level (30 mg/dL), while 4 hr fasting blood glucose
was 30 mg/dL, plasma insulin was 15.0 uIU/mL and C-pep-
tide was 4.16 ng/mL. Computed tomography (CT) of the ab-
domen demonstrated a 1.5×1.2 cm size hypervascular mass
in head portion of the pancreas (Fig. 1A) and a hypervascular
mass in the lateral segment of the liver (Fig. 1B). On admis-
sion, the fasting plasma level of gastrin was 447.0 pg/mL (0-
110 pg/mL). Somatostatin-receptor scintigraphy with [111In]
DTPA octreotide showed strong uptake of the radiotracer in
the left lateral segment at the site of the hepatic mass (Fig. 2).
In addition, laboratory studies demonstrated elevated serum
calcium (12.1 mg/dL, 8.4-10.2 mg/dL) and elevated PTH
(233.3 pg/mL, 8-76 pg/mL) was observed. Neck CT demon-
strated a 2×1 cm soft tissue mass in dorsal portion of left
thyroid, compatible with parathyroid adenoma and right thy-
roid nodule. A parathyroid Tc-
99m MIBI scan demonstrated a
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A Case of Multiple Endocrine Neoplasia Type 1 with Primary Liver
Gastrinoma
Gastrinoma is the most frequent functional pancreaticoduodenal endocrine tumor in
patients with multiple endocrine neoplasia type 1 (MEN 1). Primary hepatic gastri-
nomas in MEN 1 are very rare, with no previous reports published in the literature.
We reported the case of a 39 yr old female patient with a history of repeated peptic
ulcers and a hypoglycemia episode. Abdominal CT indicated a well-defined liver
mass and a pancreatic head mass. Somatostatin-receptor scintigraphy with [
111In]
DTPA octeotride demonstrated a strong uptake of the radiotracer in the left lateral
segment at the site of the hepatic mass. After operation, immunohistochemical stain-
ing was consistent with pancreatic insulinoma and primary hepatic gastrinoma. As
the liver is a common site of metastases from gastrinoma, primary liver gastrinoma
has not yet been reported with MEN 1. We diagnosed this patient using immunohis-
tochemical studies and treated this patient by hepatic segmentectomy.
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thyroid gland inferior pole.
The patient underwent parathyroidectomy of the left both
and right upper organ segments. 
Half of right lower segment was remained. Pathological
examination indicated parathyroid hyperplasia. The patient
was treated by Whipple’s operation. Intraoperative ultrasound
demonstrated a hypoechoic mass in pancreas head and in the
left lateral segment of the liver. The mass was not demonstrat-
ed in any other portion of pancreas or liver. Microscopic exam-
ination demonstrated a well-differentiated endocrine tumor of
the pancreas head of 1.6×1.5×0.9 cm. The patient under-
went hepatic segmentectomy of the lateral segment, which
demonstrated a well-differentiated endocrine tumor measur-
ing 1.6×1.5×0.9 cm in size. Immunohistochemical stud-
ies of the pancreas head tumor cells were positive for chromo-
granin A, synaptophysin, and insulin, while negative for gas-
trin, glucagon (Fig. 3). Immunohistochemical studies of the
liver tumor cells were positive for gastrin, while negative for
glucagon, insulin, and somatostatin (Fig. 4). Post-operatively,
the patient’s serum gastrin normalized to 34.6 pg/mL (0-110
pg/mL) rapidly, fasting blood glucose normalized to 85 mg/dL,
and fasting insulin level decreased to normal at 3.8 uIU/mL
(4-16 uIU/mL). In addition, the patient’s abdominal pain dis-
appeared and she did not exhibit neuroglycopenic symptoms.
The patient was negative for further symptoms at 3-month
intervals and had no symptoms at 1-yr postoperative. 
Based on these results, we concluded that the patient had
primary hyperparathyroidism, pituitary adenoma, pancreat-
ic insulinoma, and primary hepatic gastrinoma, resulting from
MEN 1. 
The vast majority of patients with MEN 1 display heterozy-
gotic germline mutations of the MEN 1 gene. The patient
had no familial history of endocrine tumors. Although genetic
evaluations of the patient’s family members were not perfor-
med, we will analyze clinical manifestations of MEN 1 if and
when they occur in her family members.
DISCUSSION
It is often a question in clinical and pathological practice,
whether liver tumors of unknown primary origin represent
metastases or whether they are primary to the liver. Approxi-
mately 20% of gastrinomas occur as part of the inherited tu-
mor syndrome MEN 1. Most gastrinomas are located in the
‘gastrinoma triangle’, comprising the head of the pancreas,
and the first and second parts of the duodenum (4). In rare
occasions, ectopic gastrinomas appear in other locations, such
as the stomach, the ovaries, or the liver; there have been 10
reports of primary hepatic gastrinoma identified in the litera-
ture (3,5). Primary hepatic gastrinoma tends to show the fol-
lowing qualities: occurrence in a slightly younger patient po-
pulation as compared with patients with other Zollinger Elli-
954 S.R. Lee, M.C. Choi, and K.J. Ahn
Fig. 2. Somatostatin-receptor scintigraphy with [
111In] DTPA octre-
otide showed strong uptake of the radiotracer in the left lateral seg-
ment at the site of the hepatic mass.
Fig. 1. CT scan of abdomen, (A) Arrowhead points to 1.5×1.2 cm size hypervascular mass in the pancreas head portion. (B) Arrow showed
hypervascular mass at liver lateral segment. 
A B
After 4 hr delay After 24 hr delayson Syndrome (ZES) tumors, demonstrating a predilection
for male patients, and a lack of association with the MEN 1
syndrome (6). To our knowledge, this is the first case of diag-
nosed primary hepatic gastrinoma in an MEN 1 patient.
In this report, our patient present with symptoms of hypo-
glycemia secondary to excessive secretion of insulin and had
symptoms suggestive of severe peptic ulcer disease, based on
increased gastrin levels. After performing a search on MEN 1
syndrome, we gave a diagnosis of hyperparathyroidism, insuli-
noma of pancreas, and primary hepatic gastrinoma. Based on
the patient’s past medical history of visual disturbance, amen-
orrhea, and pituitary craniectomy, we suggested she had pro-
lactinoma. The diagnosis of primary hepatic gastrinoma was
made based on both preoperative and intraoperative imaging
Primary Hepatic Gastrinoma in MEN 1 955
Fig. 3. Histopathological findings of the pancreas tumor. (A) Hematoxilin/eosin stained sections show a well differentiated pancreatic neu-
roendocrine tumor (original magnification,×100). (B) Immunohistochemical stains of neuroendocrine tumor are positive for insulin (original
magnification,×100).
A B
Fig. 4. Histopathological findings of the liver tumor. (A) Hematoxilin/eosin stained sections show a well differentiated liver neuroendocrine
tumor (original magnification,×100). (B) Immunohistochemical stains of neuroendocrine tumor are positive for gastrin (original magnifica-
tion,×100). 
A Bstudies for the location of the primary tumor, which included
CT scan, somatostatin-receptor scintigraphy, intraoperative
ultrasound, and failed to reveal any abnormalities in the pan-
creas or duodenum. Immunohistochemistry studies perfor-
med after hepatectomy revealed hepatic gastrinoma. Imm-
unohistochemical analyses of specimens obtained from the
Whipple’s operation performed on the patient revealed insuli-
noma of the pancreatic head. We believe that the disappear-
ance of all clinical manifestations after the operation substan-
tiates the evidence of primary hepatic gastrinoma.
Somatostatin-receptor scintigraphy has the advantage of
identifying tumors functionally, based on the size of the tumor
mass and the concentration of somatostatin receptors. The
disadvantage of somatostatin-receptor scintigraphy is the lack
of anatomic specificity. Nuclear medicine imaging, even with
Single photon emission computed tomography (SPECT) cro-
ss-sectional imaging, provides only general anatomic defini-
tion of surrounding organs. Somatostatin-receptor scintigra-
phy should be combined with CT scan or other anatomic im-
aging techniques to provide anatomic correlates to the scintig-
raphy findings (7).
The management of gastrinoma of MEN 1 is controversial
(8). Some have advocated a non-operative approach to gastri-
noma by controlling the effects of excess gastrin with proton-
pump inhibitors. Some recommend an operative approach if
the tumor reaches 3 cm in size, the size at which the risk of
liver metastases increases significantly. The present authors
recommend a total surgical resection of the gastrin-producing
tumor in the pancreas or duodenum, including dissection of
the regional lymph nodes. Symptom control can be achieved
by administration of highly potent proton pump inhibitors,
in up to 2-3 fold standard doses to inhibit gastric acid hyper-
secretion (9). Disagreement exists not only about the indica-
tion for surgical exploration but also about the type of oper-
ation, especially whether distal pancreatectomy or pancreati-
coduodenectomy should be preferred (4). We performed a
hepatic segmentectomy on our patients, which corrected the
patient’s overestimated gastrin level; abdominal pain disap-
peared without the use of proton pump inhibitors.
Long-term survival rates seem to be determined by the pos-
sibility of complete resection of the primary tumor by the pre-
sence of the MEN 1 syndrome (10, 11). Due to this unprece-
dented case of primary hepatic gastrinoma in MEN 1, the
prognosis was unpredictable. However, a resection of the gas-
trinoma and insulinoma with Whipple’s operation and a hep-
atic segmentectomy of the lateral segment provide a better
prognosis in this patient. 
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